Luciana Molinero to Follow-Up Studies
This is a "connection" page, showing publications Luciana Molinero has written about Follow-Up Studies.
Connection Strength
0.217
-
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019 10 23; 7(1):274.
Score: 0.104
-
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clin Lung Cancer. 2020 09; 21(5):455-463.e4.
Score: 0.027
-
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):44-59.
Score: 0.026
-
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clin Cancer Res. 2019 10 15; 25(20):6061-6072.
Score: 0.026
-
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018 Nov; 140(2):317-328.
Score: 0.024
-
TLR engagement prevents transplantation tolerance. Am J Transplant. 2006 Oct; 6(10):2282-91.
Score: 0.011